ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.

ABSTRACT:

Background

Multiple myeloma (MM) is an incurable hematological malignancy. Although proteasome inhibitors and immunomodulators have significantly improved patient outcomes, some patients respond poorly to treatment and almost all patients will relapse. Mechanisms of proteasome inhibitor resistance in multiple myeloma have not been fully elucidated. ZHX2 is a transcription regulator degraded via proteasome and presents both oncogenic or tumor suppressive effect in different cancers, however, it is still unknown that the role of ZHX2 in myeloma. In this study, we aim to demonstrate the effect and mechanism of ZHX2 on proteasome inhibitor resistance in MM.

Methods

GSE24080 gene expression profile datasets from Gene Expression Omnibus (GEO) were analyzed to evaluate the relation

SUBMITTER: Jiang J 

PROVIDER: S-EPMC7541163 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature